FDA approval of co-targeting BRAF and EGFR in colorectal cancer

April 8, 2020 FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation   — January 26, 2012 Prahallad A*, Sun C*, Huang S*, Di Nicolantonio F*, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012 […]